2008?2010
OCTOBER 2010
14 October
includes:
Managing KOLs effectively
You can never be 'too digital'
Europe - a future leader in vaccines?
SEPTEMBER 2010
15 September
includes:
Is Mobile Health just for mobile people?
Recipes for Success in India and China
Why Scotland is at the forefront of life sciences investment
AUGUST 2010
25 August
includes:
Accessing the Pharmerging Markets
Global Compliance in the Pharmerging Markets
The Trouble with Stakeholders
JULY 2010
27 July
includes:
Parallel Trade in Greece and Spain
The Zombie Economy
Choosing the Right Executive for China
JUNE 2010
23 June
includes:
The Top 50 Pharma Companies
EMA concerns over NICE
Market access in Spain
9 June
includes:
EU counterfeit crossroads
Social media — a patient's story
Market access in Italy
MAY 2010
26 May
includes:
Blockbusters are alive and well
Starting out with social media
Market access in France
12 May
includes:
Listening to social media
3D competitive analysis
Market access in the UK
APRIL 2010
27 April
includes:
Do you need a social media director
Staying ahead of the technology curve
Why is the US free market so expensive?
14 April
includes:
Managing a drug crisis
New Merck's race for the emerging markets
Using the web to improve patient compliance
MARCH 2010
24 March
includes:
Nycomed's Big Pharma plans
A chronic fatigue syndrome breakthrough?
Run your sales territory as a standalone business
10 March
includes:
The lowdown of Shire
Is there life after Big Pharma?
Don't get lost in translation
FEBRUARY 2010
24 February
includes:
The future of NICE
The EU versus animal experimentation
The seven deadly sins of marketing
10 February
Includes:
Information to patients
Reinventing market research
Named patient programmes
JANUARY 2010
26 JANuaRY
includes:
Pharma to 2020
IMI UPdate with Jonathan Knowles
The art and science of marketing
13 JANuaRY
includes:
Pipeline report 20100
Recruting and retaining R&D staff in a recession
All change at the EU
NOVEMBER 2009
25 November 2009
Includes:
M&As in 2009 - Pharma’s rollercoaster year
What can pharma learn from Toyota?
Achieve more by spending - and doing - less
11 November 2009
Includes:
What will transparency mean for pharma’s reputation?
Addressing the French funding crisis
Changing the rules
Overcoming ‘them and us’ thinking
OCTOBER 2009
28 October 2009
Includes:
Industry drug lobbyists come out on top
Daniel Vasella, the inside story
14 October 2009
Includes:
CROs and pharma: a dangerously equal partnership?
Social Media: Pharma’s black hole?
Executives: It’s time to put away childish things
SEPTEMBER 2009
30 September 2009
Includes:
The obesity pipeline - a fat chance of success?
The Innovative Medicines Initiative - is it working?
What IMI round 2 means for IT
15 September 2009
Includes:
Takeda takes on Europe
Trust is more than a marketing issue
The new hot topics in supply chain management
Straddling or focusing: the moment of truth
2 September 2009
Includes:
Boost your North American business
Shark proof your product launch
Harmony in the EU?
AUGUST 2009
26 August 2009
Includes:
What's the deal at Solvay?
The power of medical animation
18 August 2009
Includes:
Need a new non-executive director?
Sweden takes the EU reins
Patent litigation insurance: a win-win situation
11 August 2009
Includes:
Seven steps to a successful global brand
EU and FDA: working together on drug approval
Profile: Erin Gainer, HRA Pharma
5 August 2009
Includes:
Chris Viehbacher: Staging a French revolution at Sanofi-Aventis
Recession proof companies Part II: Norgine
Belgium's statin plan backfires
JULY 2009
28 July 2009
Includes:
In search of recession-proof companies: Part 1
Why pharma should embrace multi-level competition
Biotech and health outcomes in 2030
21 July 2009
Includes:
The EC antitrust report results are in. Time to pop open the champagne?
The antitrust report: a legal perspective
A quick guide to the EU's new pharmacovigilance package
Does Big Pharma still exist?
14 July 2009
Includes:
Novartis: Why we can't give free flu vaccines to poor countries
Nycomed: licensing for long-term success
Keeping up with KOLs
7 July 2009
Includes:
Big Pharma isn't dead, but long live small pharma?
Where's all the specialty pharma data?
Social media CAN work for pharma
JUNE 2009
30 June 2009
Includes:
Is the online revolution working for pharma?
Tackling neglected diseases
23 June 2009
Includes:
'Pharmerging' markets and the new world order
Finding the perfect pharma match
New EU committee leaves member states out in the cold
17 June 2009
Includes:
Why are doctors so down on pharma? A 2009 survey
Smart out-licensing to survive the 'shake-out'
Too much market focus can be a bad thing
10 June 2009
Includes:
IMI's winners and losers
Knock 'em dead with your website press centre
UK Biotech: situation critical
3 June 2009
Includes:
Belgian innovation: truffles or waffle?
Opportunities in Vietnam
New pathways in R&D
MAY 2009
27 May 2009
Includes:
So, EFPIA, where's the innovative thinking, then?
Don't miss the e-Marketing boat
Only the bad times are good for pharma
20 May 2009
Includes:
The World's top 50 pharma companies
13 May 2009
Includes:
The end of European healthcare as we know it?
Biosimilars in Europe: the story so far
Strategy solutions - the answers are out there
6 May 2009
Includes:
Breaking the glass ceiling - a report on women in pharma
Reading the 'risk radar'
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.